Aarticaine Hydrochloride (Aarticaine HCL) Powder CAS 23964-57-0

Aarticaine Hydrochloride (Aarticaine HCL) Powder CAS 23964-57-0

Product Name	Aarticaine hydrochloride
Synonyms	Aarticaine Hydrochloride;Articaine HCl; Articaine hydrochloride; Carticaine hydrochloride; HOE 045; HOE 40045; Methyl 4-methyl-3-(2-(propylamino)propionamido)-2-thiophenecarboxylate, monohydrochloride; Septanest; Septocaine; UNII-QS9014Q792; Ultracain; Ultracaine;
Molecular Formula	C18H29ClN2O
Molecular Weight	320.8354
InChI	InChI=1/C13H20N2O3S.ClH/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17) 18-4;/h7,9,14H,5-6H2,1-4H3,(H,15,16);1H
CAS Registry Number	23964-57-0
EINECS	245-957-7
Molecular Structure
Boiling point	440.6 C at 760 mmHg
Flash point	220.3 C
Vapour Pressure	5.79E-08mmHg at 25 C
Assay	99%
Appearance	White crystalline powder

Aarticaine Hydrochloride Description:

1.Recently, there has been an interest in the use of Aarticaine hydrochloride as a dental local anesthetic solution. It has been reported that the use of lysine hydrochloride as a localized anesthetic is safe and effective. Anesthesia is due to the use of such local anesthetics in dentistry, especially after giving nerve block injections, rare but undesirable adverse reactions.

2.There is no evidence to support the idea that the use of aspirin has a greater risk of associated Aarticaine hydrochloride than the use of any other local anesthesia. Clinical relevance: The purpose of this paper is to review the relative merits of the potential shortcomings of clenafine hydrochloride. The article will also be intended to update the reader’s use of local analgesia in carnitine hydrochloride in dentistry, including pharmacological, efficacy and safety issues (including the risk of nerve sensation) that are commonly associated with the administration of the drug.

Aarticaine Hydrochloride Applications:

The use of Aarticaine hydrochloride results in inhibition of neuronal activity. Depression makes the nervous system become allergic, causing anxiety and vibration, leading to mild to severe convulsions. Animal studies have shown that the use of procaine in the brain can increase the level of dopamine and serotonin in the brain. Other problems may vary depending on the individual’s tolerance to the procaine dose. Central nervous system excitation can cause tension and dizziness, if excessive coordination may lead to respiratory failure. Procaine may also cause myocardial ischemia leading to cardiac arrest.

Aarticaine hydrochloride can also cause allergic reactions, leading to individual breathing, rash and swelling and other issues. The allergic reaction to procaine is usually not against procaine itself, but its metabolite PABA. Approximately one of about 3,000 people has an atypical form of pseudo-alkaline esterase, which does not require hydrolysis of ester anesthetics such as procaine, resulting in increased levels of narcotics in the blood and increased toxicity.

Aarticaine Hydrochloride COA:

Articaine Hydrochloride Dosage:

Adults
Dental Anesthesia
Submucosal Injection
Usual dosage range: 20–204 mg.

Recommended Dosages (as articaine hydrochloride 4% with epinephrine 1:100,000) for Dental Anesthesia in Healthy Adults

Prescribing Limits:

Pediatric Patients

Dental Anesthesia
Submucosal Injection
Maximum 7 mg/kg (0.175 mL/kg).

Adults
Dental Anesthesia
Submucosal Injection
Maximum 7 mg/kg (0.175 mL/kg).

Special Populations

Hepatic Impairment
Reduce dosage in patients with hepatic disease.